By making large amounts of diverse data widely available, healthcare institutions can feel confident about the evaluation, creation, and validation of algorithms as they're transitioned from ideation to use.
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Don’t bet so big on AI solutions with “someday potential” that you ignore tools that can solve challenges and generate ROI now. Here are five critical AI investments that provide “right now” value for health systems, clinicians and patients.
Do some people simply think the A in AI stands for Automation? Most likely the confusion is due to a lack of understanding of what AI truly is, combined with a strong desire to use the term for marketing purposes.
Biotech startups raised $2.6 billion globally in the second quarter of this year, but that’s down nearly 46% compared to the same period last year, according to a report from Pitchbook. Capital is harder to find, and the report projects an uptick in M&A activity as companies run out of cash.
UltraSight, based in Israel, recently received a nod from the FDA to market its UltraSight AI Guidance product that can assist medical professionals without sonography experience in acquiring cardiac ultrasound images and allow for more widespread detection of heart diseases.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.
A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the possibility of joining forces with Nvidia in research.
There are three key areas of the healthcare sector where generative AI is booming the most — in terms of both venture capital funding and the development of innovative technology — according to Anjalika Komatireddy, an analyst at CB Insights. During a recent webinar, she discussed the generative AI activity occurring in these three areas: care delivery and navigation, digital therapeutics and drug discovery.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
With few workers entering a field dominated by older Gen X-ers and Baby Boomers, there’s a growing gap in skilled medical coders — people who read notes from doctors and apply appropriate codes for billing and reimbursement purposes. So many are turning to AI.
Eyenuk recently received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system, which automatically detects diabetic retinopathy. The company said this FDA clearance makes its system the only AI system that is FDA-cleared for use with multiple retinal cameras produced by different manufacturers.
Losing sight of organizational goals and priorities and operating without a clear, supported plan can lead to a scatter-shot approach to AI investment that may duplicate investments, misallocate resources, and cause stakeholders to become cynical about AI’s value and potential.
The use of LLMs in healthcare is still incredibly nascent, so many experts are calling for a safety framework to make this uncharted territory feel safer. There are still a lot of unknowns, but avoiding clinical use cases and not inputting patients’ health information seem to be the most important guardrails providers are putting around LLMs at the moment.
At a time when the vast majority of people are just beginning to hear and learn about artificial intelligence, it is critical that technology executives make a concerted effort to reinforce its purpose and intent.